Beyond Erythropoiesis: Emerging Metabolic Roles of Erythropoietin

  1. Meredith Hawkins2
  1. 1Toronto General Research Institute and Division of Endocrinology, Department of Medicine, University Health Network, University of Toronto, Toronto, Ontario, Canada
  2. 2Diabetes Research and Training Center, Albert Einstein College of Medicine, Bronx, NY
  1. Corresponding author: Meredith Hawkins, meredith.hawkins{at}einstein.yu.edu.

Infiltration of inflammatory cells into adipose tissue causes insulin resistance in animal models and is associated with insulin resistance in humans (1,2). Among potential therapeutic approaches, the hormone erythropoietin (EPO) exerts anti-inflammatory effects in a variety of nonerythroid tissues (3), in which the receptor for EPO (EPO-R) is widely expressed (4). Various observations suggest a relationship between EPO and diabetes. There is an increased prevalence of anemia with inadequate EPO response in diabetes (5), and treatment of anemia slows the progression of microvascular and macrovascular complications (6). EPO reduced glucose levels in nondiabetic humans (7) and reduced diet-induced obesity and suppressed gluconeogenesis in rodents (8,9). While EPO increases adipose tissue oxidative metabolism and deletion of EPO in adipocytes results in obesity (10), failure to reproduce this highlights potential genetic and environmental influences (11). EPO has cytoprotective, proliferative, and anti-inflammatory effects in a …

No Related Web Pages
| Table of Contents
OPEN ACCESS ARTICLE

This Article

  1. doi: 10.2337/db14-0566 Diabetes vol. 63 no. 7 2229-2231
  1. Free via Open Access: OA